EMA Authorised: Pegasys (peginterferon alfa-2a) — pharmaand GmbH

View source ↗

Summary

EMA authorised Pegasys (peginterferon alfa-2a) for chronic hepatitis C, chronic hepatitis B, polycythemia vera, and essential thrombocythemia, with decision dat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Hepatitis B
• Hepatitis C
• Polycythemia Vera

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Status: Authorised. Therapeutic area: Hepatitis C, Chronic;Hepatitis B, Chronic;Polycythemia Vera;Thrombocythemia, Essential. MAH: pharmaand GmbH. Decision date: 31/10/2025